CELL INTELLIGENCE · 肿瘤细胞治疗研究

线粒体适应度作为癌症中的功能性免疫检查点：代谢可塑性、肿瘤演化与免疫治疗

Mitochondrial Fitness as a Functional Immune Checkpoint in Cancer: Metabolic Plasticity, Tumor Evolution, and Immunotherapy.

辐照 CD19 嵌合抗原受体 YTS 细胞保留抗肿瘤活性并可作为自体 CAR-T 疗法的可规模化替代方案

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

实体瘤 CAR-T 细胞工程化：克服抗原、迁移与微环境屏障

Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers.

可编程工程菌调控代谢并原位重塑 TME 以增强过继性细胞治疗

Programmable engineered bacteria manipulate metabolism and remodel the TME in situ for enhancing adoptive cell therapy.

超越传统嵌合抗原受体：拓展 CAR-T 细胞疗法中的可靶向抗原版图

Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy.

CAR-T 细胞治疗指南：研发、现状与未来前景

A guide to CAR T cell therapies: development, current status and future prospects.

2024 EBMT 活动报告：跨越 100 万例造血细胞移植和 20, 000 例 CAR-T，细胞治疗领域的里程碑

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

CAR-T 细胞基因治疗的综合评价：追溯其革命性临床突破与迈向下一代工程的进展

A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engin

基于这些进展，我们假设 CAR-T 疗法正经历从单靶点细胞毒性向多功能、可编程框架的范式转变，该框架能够克服耐药性、增强安全性，并实现实体瘤的有效渗透。

Lisaftoclax 联合伊沙佐米和地塞米松在 CAR-T 后用于不适合移植的复发/难治性超高危多发性骨髓瘤维持治疗：两例病例报告及文献综述

Lisaftoclax combined with ixazomib and dexamethasone after CAR-T for maintenance therapy in transplant-ineligible relapsed/refractory ultra-high-risk